The GOLGA3 Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the GOLGA3 gene in a human lung adenocarcinoma epithelial background. This loss-of-function model is generated through CRISPR/Cas9-mediated gene disruption, yielding a heterogeneous pool of edited cells that enables the study of GOLGA3-dependent cellular processes without clonal selection. The polyclonal format retains population diversity while providing a robust tool for investigating Golgi biology and membrane trafficking in cancer cells.
The host cell line, NCI-H1975, is a well-characterized human non-small cell lung cancer (NSCLC) line derived from the pleural effusion of a female patient with adenocarcinoma. These cells harbor activating EGFR L858R and T790M mutations, making them a clinically relevant model for studying EGFR-targeted therapy resistance in NSCLC. The epithelial origin and genetic profile of NCI-H1975 provide a physiologically appropriate context for examining how Golgi disruptions influence oncogenic signaling and therapeutic responses.
GOLGA3 (golgin A3) is a peripheral membrane protein of the Golgi apparatus critical for maintaining Golgi ribbon integrity and tethering vesicles during membrane trafficking. It functions in concert with Rab GTPases, other golgin family proteins, and the dynein-dynactin motor complex to regulate COPI and COPII vesicle transport. GOLGA3 activity is modulated upstream by cell cycle kinases and mitotic kinases, and its disruption leads to downstream defects in Golgi morphology, protein glycosylation, and secretion. The mechanistic summary indicates that GOLGA3 knockout impairs Golgi ribbon organization, which in turn compromises glycosylation and vesicular trafficking, potentially altering cell surface receptor presentation and secretory pathway function.
In the NCI-H1975 context, loss of GOLGA3 may significantly impact EGFR trafficking and signaling dynamics, given the reliance of receptor tyrosine kinases on proper Golgi function for maturation and localization. Altered glycosylation patterns and secretion caused by GOLGA3 disruption could modify cell surface receptor expression, ligand responsiveness, and microenvironmental interactions, thereby influencing drug resistance mechanisms. This polyclonal knockout model thus offers a powerful system to dissect how Golgi structural proteins contribute to NSCLC pathobiology and therapeutic sensitivity.
Researchers can employ this knockout model in a variety of assays to explore Golgi dysfunction and its implications in cancer biology. Representative applications include western blotting to confirm GOLGA3 protein depletion, immunofluorescence with Golgi markers such as GM130 to assess morphological changes, and lectin-based glycosylation analysis to evaluate glycoprotein processing. Functional studies can incorporate cell proliferation, migration, and drug sensitivity profiling to link Golgi integrity to tumor cell behavior and therapeutic responses. For more information or to order this product, please contact Ascent Research.
